An observational study in Breast Cancer, sponsored by Masaryk Memorial Cancer Institute. Recruiting at 1 site in Czechia. Open to female participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Masaryk Memorial Cancer Institute · Observational
This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls.
The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.
The study will include women aged 20-55 years. Patients with breast cancer will be enrolled at different stages of their disease and treatment, including newly diagnosed treatment-naive patients, patients who have completed chemotherapy, patients receiving endocrine therapy without prior chemotherapy, and patients undergoing follow-up after treatment.
In patients with breast cancer, hormonal measurements will be obtained as part of routine clinical care, based on the treating physician's decision. No additional study-specific blood sampling or interventions will be performed. Relevant clinical data will be collected from medical records.
Healthy volunteers will undergo a single blood sampling procedure and complete a brief questionnaire covering gynecological history, smoking status, and body mass index (BMI).
The hormonal assessment will include serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4).
The collected data will be used to describe hormonal profiles in both study populations and assess the feasibility of routine AMH testing in clinical practice. The findings may provide preliminary data for future research on the clinical utility of AMH in women with breast cancer.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 200 is close to the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Masaryk Memorial Cancer Institute is the lead sponsor of 15 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of women aged 20-55 years, including patients with breast cancer at different stages of disease and treatment and healthy female volunteers. Breast cancer patients will be identified during routine clinical care, while healthy volunteers will be recruited on a voluntary basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women aged 20-55 years with breast cancer at different stages of disease and treatment, including newly diagnosed treatment-naive patients, patients who have completed chemotherapy, patients receiving endocrine therapy without prior chemotherapy, and patients undergoing follow-up after treatment.
Healthy women aged 20-55 years without a history of breast cancer.
Serum Anti-Müllerian Hormone (AMH) Levels
Serum AMH concentrations will be measured in women with breast cancer at different stages of treatment and in healthy female controls. The distribution of AMH levels will be described in both study populations.
Time frame: Baseline (At the time of blood sampling)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.
Of 1,191 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 19 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Masaryk Memorial Cancer Institute